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Abstract: Ciclesonide is a nonhalogenated corticosteroid that is converted to its clinically
active metabolite, desisobutyryl-ciclesonide, by esterases in the airways. Pharmacodynamic
studies have shown that inhaled ciclesonide has potent antiinflammatory activity in patients
with asthma, and does not appear to have clinically relevant systemic effects, even at high
doses. It is highly protein-bound and rapidly metabolized by the liver, and thus has a low oral
bioavailability. Ciclesonide is formulated as a solution for inhalation using a hydrofluoroalkane
pressurized metered-dose inhaler. This formulation delivers a high fraction of respirable
particles that yield high lung deposition with even distribution throughout the lungs and minimal
oropharyngeal deposition. Results from numerous 12-week trials in patients (including
children) with varying degrees of asthma show that morning or evening dosing with ciclesonide
is more effective than placebo, and at least equivalent to other inhaled corticosteroids such as
budesonide and fluticasone, with regard to improved spirometry, symptom scores, and less
need for rescue medication. Results with once-daily ciclesonide are similar to those with
twice-daily budesonide or fluticasone. At the dosages used in clinical trials, ciclesonide did
not exert any untoward adverse effects and did not affect cortisol production. The favorable
pharmacological properties of ciclesonide help explain the low incidence of adverse events,
which are mostly mild to moderate in nature. Once-daily ciclesonide offers an efficacious
treatment option for stepwise asthma management when inhaled corticosteroids are required.
Keywords: ciclesonide, asthma, inhaled corticosteroids, adults, children
Introduction
The number of persons worldwide with asthma has increased to around 300 million,
and may reach 400 million by 2025 (GIA 2005). The reasons for this dramatic increase
are under investigation and may relate to adoption of Western lifestyles and
urbanization (GIA 2005). About 1% of all disability-adjusted life years are lost due
to asthma, and asthma accounts for 1 in every 250 deaths worldwide (GIA 2005).
Asthma is characterized by bronchospasm and inflammation, and airway remodeling
may occur in some patients – all of which can result in moderate and severe persistent
disease requiring long-term management (NAEPP 2002).
There is a problem with under-diagnosis of asthma (Hasselgren et al 2001) and,
once diagnosed, with inadequate management of underlying inflammation,
particularly in patients with intermittent disease. A study in adolescents with mild
intermittent asthma found evidence of persistent airway inflammation, which suggests
that these patients may benefit from early intervention with inhaled corticosteroids
(ICS) (Spallarossa et al 2003). Such intervention in mild persistent asthma improves
asthma control and reduces the risk of severe asthma exacerbations (Pauwels et al
2003).
Inhaled corticosteroids are the cornerstone of asthma therapy and are
recommended for daily control of mild, moderate, and severe persistent asthma in
adults and children (GIA 2004). While the established efficacy of ICS in asthma has
led to their acceptance as first-line control of persistent asthma (GIA 2004), their use
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may be limited by local adverse effects such as oral
candidiasis, and there is some concern about potential long-
term systemic effects, including cortisol suppression, growth
retardation in children, and risk of osteoporosis and fractures
(Ellepola and Samaranayake 2001; Salvatoni et al 2003;
Hubbard and Tattersfield 2004). Ciclesonide is a new once-
daily ICS with similar efficacy to other ICS in asthma, and
it possesses potential advantages in terms of reduced local
and systemic adverse effects. It is available as 80 µg and
160 µg inhalers. Each actuation delivers either 80 µg or
160 µg of ciclesonide from the mouthpiece (ex-actuator).
In the following review, some studies reported the
ciclesonide dose released from the valve, ie, ciclesonide
100 µg or 200 µg ex-valve, which are equivalent to
ciclesonide 80 or 160 µg ex-actuator, respectively.
Pharmacology
Pharmacokinetics
Ciclesonide is a nonhalogenated ICS that is formulated as a
solution for inhalation in a hydrofluoroalkane (HFA)
pressurized metered-dose inhaler (MDI). This device
delivers ciclesonide in fine particle spray (average particle
size 1.1–2.1 µm) that yields a high fraction of respirable
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Figure 1 Deposition characteristics of ciclesonide: (a) Mean (± SD) percentage of a single dose of 
99mTc-ciclesonide 320 µg deposited in the lung, oropharynx,
esophagus, stomach, or exhaled air filter, in 12 adult patients with asthma (measured by 2D gamma-scintigraphy) (Newman et al 2004); (b) Relative oropharyngeal
deposition of ciclesonide 800 µg inhaled via HFA MDI and desisobutyryl-ciclesonide (des-CIC) compared with budesonide 800 µg inhaled via CFC MDI in the first
hour following administration, as measured in oropharyngeal wash samples from 18 healthy volunteers (values were calculated using molar dose-adjusted area under
the curve data) (Nave R, Zech K, Bethke TD. 2005b. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared
with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 61:203-8. Copyright © 2005. Reproduced with permission from
European Journal of Clinical Pharmacology); (c) Relative oropharyngeal deposition of ciclesonide 800 µg inhaled via HFA MDI and des-CIC compared with fluticasone
propionate 1000 µg inhaled via HFA MDI in the first hour following administration in 18 patients with asthma.(Richter et al 2005).
*p  < 0.0001 versus active comparator.
† p < 0.001 versus active comparator.
Abbreviations: CIC, ciclesonide; CFC, chlorofluorocarbon; HFA, hydrofluoroalkane; MDI, marked-dose inhaler; SD, standard deviation.
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particles (Rohatagi, Derandorf, et al 2003; Newman et al
2004; Rohatagi et al 2004). In adult patients with asthma,
inhalation of a single dose of 
99mTc-labeled ciclesonide
320 µg resulted in a mean of 52% of the ex-actuator dose
reaching the lungs (Newman et al 2004). Deposition of
ciclesonide within the lung was highest (approximately
55%) in the outermost regions, ie, small airways and alveoli.
Oropharyngeal deposition of ciclesonide 800 µg (via HFA
MDI) was half that of budesonide 800 µg (via chlorofluoro-
carbon [CFC] MDI), and conversion of ciclesonide to its
active metabolite in the upper oropharynx was very low in
a randomized, open-label, sequential treatment study in 18
healthy subjects (Nave, Zech, et al 2005). Oropharyngeal
deposition of ciclesonide was also significantly lower than
fluticasone in a study of 18 patients with asthma (Figure 1)
(Richter et al 2005).
Animal (Nave, Meyer, et al 2005) and in vitro (Nave et
al 2003) studies showed that ciclesonide is converted by
esterases in lung tissue to the pharmacologically active
metabolite, desisobutyryl-ciclesonide (des-CIC), which has
a 100-fold greater glucocorticoid receptor binding affinity
than ciclesonide (Stoeck et al 2004). An in vitro study in
human lung tissue slices showed a high proportion of des-
CIC conjugation with fatty acids (Nave et al 2003). These
lipid conjugates of des-CIC may explain the prolonged local
antiinflammatory action of ciclesonide in the lung and its
clinical efficacy with once-daily dosing.
The pharmacokinetics of ciclesonide and des-CIC were
equivalent in 12 healthy volunteers and 12 patients with
asthma after inhalation of a single dose of ciclesonide
1240 µg (ex-actuator MDI) (Bethke et al 2003). Pooled
pharmacokinetic data from 151 healthy subjects and patients
with asthma who participated in phase I studies show des-
CIC has a clearance of 396 L/hr and a volume of distribution
of 1190 L (Rohatagi, Arya, et al 2003).
Ciclesonide and des-CIC are highly protein-bound
(~99%), which is an advantage over other ICS because it
results in a low proportion of free, unbound drug in the
systemic circulation (Rohatagi et al 2005) (Figure 2). In
vitro studies show that ciclesonide is metabolized by
hepatocytes to des-CIC within the first hour of exposure
(Gu et al 2004). Des-CIC is, in turn, extensively metabolized
to inactive metabolites (Nave et al 2003; Gu et al 2004).
Elimination of des-CIC and other metabolites is
predominantly through the feces (Nave, Bethke, et al 2004).
Because of extensive first-pass metabolism, the systemic
bioavailability of des-CIC after oral ingestion is < 1% (Nave,
Bethke, et al 2004). Thus, any ciclesonide swallowed after
oral inhalation does not contribute to the systemic
availability of the drug or its active metabolite. In addition,
low systemic exposure to unbound des-CIC suggests a low
potential for systemic adverse events after oral inhalation.
Pharmacodynamics
Up to one third of des-CIC may be converted to lipophilic
fatty acid esters that reside in lung tissue (Nave, Schmidt,
et al 2004). Binding affinity of des-CIC to glucocorticoid
receptors is comparable with budesonide (Stoeck et al 2004)
and fluticasone (Belvisi et al 2005), and potent dose-
dependent antiinflammatory activity in human bronchial
epithelial cells have been described (Serpero et al 2004).
Studies in rats showed that ciclesonide prevented and
reversed allergic airways inflammation and remodeling
(Leung et al 2005).
Inhaled ciclesonide (800 µg dry powder via Cyclohaler
®
twice daily for one week) reduced early- and late-phase
reactions, compared with placebo, after allergen challenge
in patients with asthma (Larsen et al 2003), and a minimally
effective dose of 80 µg once daily was identified (Gauvreau
et al 2005). Ciclesonide also reduced airway responsiveness
to adenosine-5´-monophosphate (AMP) in a dose-dependent
manner (100–1600 µg dry powder via Cyclohaler daily) in
29 patients with mild to moderate asthma (Taylor et al 1999).
Ciclesonide (400 µg ex-valve HFA MDI in the morning)
reduced airway responsiveness and inflammation similar
to budesonide (400 µg via Turbuhaler
®) in 15 patients with
mild asthma (Kanniess et al 2001). Reduced methacholine
or AMP hyperresponsiveness was observed with dosages
of ciclesonide (400–1600 µg ex-valve HFA MDI) and
fluticasone (500–2000 µg ex-valve CFC MDI) in two studies
of patients with asthma (Lee et al 2004; Derom et al 2005).
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Figure 2 Fraction of free, unbound drug in plasma for des-CIC (Rohatagi et al
2005), fluticasone propionate (FP) (Rohatagi et al 1996), budesonide (BUD)
(Ryrfeldt et al 1982), beclomethasone dipropionate (BDP) (Martin et al 1975),
and flunisolide (FLU) (Mollmann et al 1997).Therapeutics and Clinical Risk Management 2006:2(1) 28
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Figure 3 Effects of ciclesonide treatment on serum cortisol levels: (a) Mean (± SD) 24-hour serum cortisol levels in 12 healthy male subjects on day 7 of treatment
with either placebo or ciclesonide in a randomized, double-blind, cross-over study (Weinbrenner A, Huneke D, Zschiesche M, et al. 2002. Circadian rhythm of serum
cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab. 87:2160–3. Copyright © 2002. Reproduced with permission from the
Endocrine Society); (b) Mean change from baseline in serum cortisol levels after 12 weeks of treatment in adult patients with mild to moderate persistent asthma
randomized to receive placebo (n = 41), ciclesonide 320 µg once daily (n = 40), ciclesonide 320 µg twice daily (n = 42), or fluticasone propionate 440 µg twice daily
(n = 41) (Lipworth BJ, Kaliner MA, LaForce CF, et al. 2005. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-
moderate persistent asthma. Ann Allergy Asthma Immunol. 94:465–72. Copyright © 2005. Reproduced with permission from the American College of Allergy, Asthma, &
Immunology). Serum cortisol levels were measured following sequential stimulation with (i) low-dose (1 µg) and (ii) high-dose (250 µg) cosyntropin. Changes observed
with ciclesonide treatment were not statistically different from placebo.
*p  < 0.0001 versus active comparator.
† p < 0.001 versus active comparator.
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Attenuation of exercise-induced bronchoconstriction by
ciclesonide (40–320 µg ex-actuator MDI daily) was found
in a study of 26 affected adults (Subbarao et al 2005).
Treatment with ciclesonide does not appear to have a
clinically relevant effect on serum cortisol (Figure 3). There
was no difference in serum cortisol concentrations when
inhaled ciclesonide (800 µg ex-valve MDI daily for 7 days)
was compared with placebo in 12 healthy volunteers
(Weinbrenner et al 2002). Placebo-controlled studies in
patients with asthma showed similar results at dosages up
to 1280 µg (ex-actuator HFA MDI) daily for as long as
12 weeks (Chapman et al 2002; Ukena et al 2003; Kerwin
et al 2004; Derom et al 2005; Lipworth et al 2005). In studies
of up to 12 weeks’ duration, ciclesonide (320–1280 µg
ex-actuator HFA MDI daily) had significantly less effect
on cortisol production than fluticasone propionate (880–
1760 µg daily, ex-actuator HFA MDI or CFC MDI) (Derom
et al 2005; Lee et al 2005; Lipworth et al 2005). An analysis
of 17 trials in adults and children with asthma showed that
inhaled ciclesonide (up to 1280 µg daily) had a negligible
effect on endogenous cortisol concentrations (Pfister et al
2004). Switching to ciclesonide (800–1600 µg ex-valve MDI
daily for up to 52 weeks) following high-dose therapy with
another ICS was found to improve serum cortisol and
markers of bone formation (O’Connor, Kilfeather, et al 2002;
O’Connor, Sips, et al 2002). Short-term lower-leg growth
rate was not affected by inhaled ciclesonide (40–160 µg HFA
MDI daily for 2 weeks) in a study of 24 children with asthma
(Agertoft and Pedersen 2005).
Clinical studies
Efficacy
Ciclesonide has been studied in numerous 12-week trials
with comparison against baseline, placebo, and other ICS
(Table 1). A placebo-controlled study of ciclesonide (80 or
320 µg ex-actuator HFA MDI each morning over 12 weeks)
given to 360 patients with bronchial asthma (previously
treated with constant beclomethasone dipropionate) showed
that both dosages significantly improved peak expiratory
flow (PEF) and forced expiratory volume in 1 second (FEV1)
compared with placebo (Langdon et al 2005). These results
were corroborated in a similar 12-week trial of 329 patients
with persistent asthma (Chapman et al 2005). Compared
with placebo, ciclesonide 160 or 640 µg (ex-actuator HFA
MDI) once daily in the morning were equally effective at
maintaining morning PEF (p < 0.0001 for both doses), FEV1
(p < 0.05) and forced vital capacity (FVC) (p < 0.05)
(Chapman et al 2005). An open extension of this trial showed
that ciclesonide was effective over a period of 52 weeks
(Chapman et al 2002). A collation of 2 identical placebo-
controlled trials in 1015 patients with mild to moderate
asthma showed that ciclesonide (80, 160, or 320 µg ex-
actuator HFA MDI daily for 12 weeks) significantly
improved FEV1 (p = 0.0007, p = 0.0004, p < 0.0001,
respectively) and reduced symptoms (p < 0.0001 for all
dosages), daily albuterol use (p < 0.0001), and dis-
continuations (p < 0.0001) compared with placebo
(Pearlman et al 2005). These results confirmed findings from
a 12-week trial of ciclesonide 400 versus 800 µg (ex-valve
MDI) twice daily in 365 patients with asthma pretreated
with high-dose ICS, where improved PEF and a decrease in
symptoms and rescue medications were found after
12 weeks of therapy (both doses produced equivalent results)
(O’Connor, Sips, et al 2002). FEV1 improvements were
maintained over a 40-week open extension of this study
(O’Connor, Kilfeather, et al 2002).
A study in 209 patients with bronchial asthma showed
that ciclesonide 200 µg (ex-valve HFA MDI) for 8 weeks
may be given in the morning or evening to produce signifi-
cant improvements in symptoms (at least p < 0.001 compared
with baseline), spirometry (p < 0.05), and rescue medication
usage (p < 0.05), with evening dosing significantly
improving morning PEF (p < 0.05 compared with morning
dosing) (Postma et al 2001).
Compared with other ICS
Ciclesonide has been compared with budesonide and
fluticasone in several studies (Table 1). In 554 patients with
asthma, ciclesonide 80 or 320 µg (ex-actuator HFA MDI)
each morning was equal in efficacy to budesonide 200 µg
via (Turbuhaler) twice daily for 12 weeks with regard to
significant improvements in FEV1, FVC, PEF, asthma
symptoms, and use of rescue medication (Hansel et al 2004).
Similar 12-week efficacy to budesonide (200 µg ex-valve
MDI twice daily) was found with ciclesonide (160 µg ex-
actuator MDI, morning or evening) in a study of 404 patients
pretreated with ICS (Gadgil et al 2005). FEV1 was
maintained, and level of symptoms and use of rescue
medications were decreased or remained stable with all
regimens. Evening doses of ciclesonide (320 µg ex-actuator
HFA MDI) and budesonide (400 µg via Turbuhaler) have
been compared over 12 weeks in 399 patients with asthma
(Ukena et al 2003). Ciclesonide produced significantly better
FEV1 (p < 0.0185) and FVC (p < 0.0335) results than
budesonide and produced an earlier onset of morning PEF
improvement (day 3 vs week 2). Once-daily morningTherapeutics and Clinical Risk Management 2006:2(1) 30
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Table 1 Efficacy and tolerability of ciclesonide in patients with asthma in clinical studies of 12 weeks’ duration
Study
design Dosages Overall Tolerability and
Study (n) Inclusion criteria (µg) Main results efficacy quality of life
Langdon et al 2005 mc, r, pg, Low–moderate-dose ICS; C 80 od am PEFam: C80 > P (p = 0.0012); C > P Safe and well
db, P FEV1 60%–90% C 320 od am C320 > P (p = 0.0006) tolerated
n = 360 predicted; PEFpm: C80 > P (p = 0.0121); Serum and urinary
demonstrated C320 > P (p = 0.0048) cortisol levels:
reversibility FEV1: C80 > P (p = 0.0044); C80 ≡ C320 ≡ P
C320 > P (p = 0.0001)
FVC: C80 > P (p = 0.0203);
C320 > P (p = 0.0197)SR:
C > P (p < 0.0001 change from BL)
Resc: C < P (p < 0.01 change
from BL)
LOE: C80 > P (p ≤ 0.0052);
C320 > P (p < 0.0001);
C320 > C80 (p = 0.0087)
Chapman et al 2005 mc, r, pg, Moderate-dose ICS; C 160 od am PEFam: C160 ≡ C640 > P C160 ≡  Cortisol levels:
db, P FEV1 60%–90% C 640 od am (p < 0.0001 AD) C640 > P C160 ≡ C640 ≡ P
n = 329 predicted; FEV1: C160 ≡ C640 > P (p < 0.05 AD)
demonstrated FVC: C160 ≡ C640 > P (p < 0.05 AD)
reversibility SR: C > P (p ≤ 0.0006 change
from BL)
Resc: C < P (p < 0.0001 change
from BL)
LOE: P > C160 ≡ C640
(p < 0.0001 AD)
Berger et al 2004;  mc, r, pg, Mild to moderate asthma; C 80 od FEV1: C80 > P (p = 0.0007); C > P Oral candidiasis:
Nayak et al 2005; db, P FEV1 60%–85% C 160 od C160 > P (p = 0.0004); C ≡ PHPA function:
Pearlman et al 2005 n = 1015 predicted; C 320 od C320 > P (p < 0.0001) C had no effect
≥ 12 years old SR: C > P (p < 0.0001 AD) Overall AQLQ: C80,
Resc: C < P (p < 0.0001 AD) C160, C320 > P
LOE: C < P (p < 0.0001 AD) (p < 0.0001 AD)
O’Connor,  Sips,  r, pg, db High-dose ICS; PEF am C 400 bid PEFam: C800 > BL (p = 0.0002); C400 Safe and well
et al 2002 n = 365 ≤ 80% predicted; C 800 bid C1600 > BL (p = 0.001) bid ≡ C800 tolerated
demonstrated (C ex-valve) SR: C > BL (p < 0.0001 AD) bid > BL Serum and urinary
reversibility; Resc: C800 < BL (p = 0.0045); cortisol levels: C > BL
symptom scores ≥ 4 last C1600 ≡ BL (p = 0.0758) (p < 0.05 AD)
week; Serum osteocalcin
resc ≥ 14 puffs last week levels: C > BL
(p < 0.05 AD)
Postma et al 2001  r, pg, db
a Mild to moderate asthma; C 200 od am PEFam: Cpm > Cam (p < 0.05) ≡ BL Cam ≡  Safe and well
n = 209 FEV1 50%–90% C 200 od pm PEFpm: Cpm > BL (p < 0.05) ≡ Cam Cpm > BL tolerated
predicted; (C ex-valve) FEV1: Cam ≡ Cpm > BL (p < 0.05) Urinary cortisol
demonstrated FVC: Cam ≡ Cpm > BL (p < 0.05)  excretion:
reversibility; SR: Cam ≡ Cpm > BL (p < 0.001) Cam ≡ Cpm ≡ BL
resc meds only during Resc: Cam ≡ Cpm < BL (p < 0.05)
past 4 weeksTherapeutics and Clinical Risk Management 2006:2(1) 31
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Table 1 continued
Study
design Dosages Overall Tolerability and
Study (n) Inclusion criteria (µg) Main results efficacy quality of life
Hansel et al 2004  r,pg,db(C); FEV1 50%–90% predicted C 80 od am PEFam: C80 ≡ C320 ≡ Bu > BL C80 ≡  Urinary cortisol
open (Bu) C 320 od am (p < 0.0001) C320 ≡ Bu  excretion:
n = 554 Bu 200 bid PEFam: C80 ≡ C320 ≡ Bu > BL > BL C80 ≡ C320 ≡ BL
(Turbuhaler®)( p  < 0.0001) Bu < BL (p < 0.05)
FEV1:C80 ≡ C320 ≡ Bu > BL
(p < 0.0001)
FVC: C80 ≡ C320 ≡ Bu > BL
(p < 0.0001)
SR: C80 ≡ C320 ≡ Bu > BL
(p < 0.0001)
Resc: C80 ≡ C320 ≡ Bu < BL
(p < 0.0001)
Gadgil et al 2005  NR Low-dose ICS; C 160 od am FEV1: Cam ≡ Cpm ≡ Bu ≡ BL Cam ≡  NR
n = 404 FEV1 ≥ 70% predicted; C 160 od pm SR: Cam ≡ Cpm ≡ Bu ≡ BL Cpm ≡ Bu
2-week run-in with Bu 200 bid Resc: Cam ≡ Cpm ≡ Bu ≡ BL
Bu 200 µg twice daily (pMDI) LOE: Cam ≡ Cpm ≡ Bu ≡ BL
Ukena et al 2003  mc, r, pg, FEV1 50%–90% C 320 od pm FEV1: C > Bu (p = 0.0185) > BL C > Bu  Urinary cortisol
db, dd predicted Bu 400 od pm (p < 0.0001) > BL levels: C ≡ Bu ≡ BL
n = 399 (Turbuhaler
®) FVC: C > Bu (p = 0.0335) > BL
(p < 0.0001)
PEFam: C > Bu (earlier onset)
SR: C ≡ Bu > BL
Boulet et al 2003  mc, r, pg, Moderate-dose ICS C 320 od am FEV1: C ≡ Bu C ≡ Bu NR
db then Bu 1600 µg Bu 400 od am FVC: C > Bu (p < 0.01)
n = 359 od × 2–4 weeks; (Turbuhaler
®) SR: C > Bu (p = 0.0288)
b
FEV1 65%–90% Resc: C ≡ Bu
predicted on Bu
Buhl et al 2004  mc, r, db FEV1 80%–100% C 160 od pm PEFam: C ≡ F > BL (p < 0.0001) C ≡ FN R
n = 529 predicted, pretreated F 88 bid FEV1: C ≡ F > BL (p < 0.0001)
with low-dose ICS; FVC: C ≡ F > BL (p < 0.0001)
FEV1 50%–90% SR: C ≡ F > BL (p < 0.0001)
predicted after Resc: C ≡ F < BL (p < 0.0001)
1–4 weeks without ICS
Magnussen mc,  r,  db 1–4  weeks without ICS; C 80 od pm FEV1: C80 ≡ C160 ≡ F > BL C80 ≡ C160 ≡ FN R
et al 2005 n = 697 FEV1 61%–90% C 160 od pm (p < 0.0051 AD)
predicted; F 88 bid SR: C80 ≡ C160 ≡ F > BL
12–75 years old (p < 0.0001 AD)
Resc: C80 ≡ C160 ≡ F > BL
(p < 0.0001 AD)
Bernstein et al  mc, r, pg, db, Moderate to severe C 160 bid FEV1: C320 > P (p = 0.0374); C ≡ F Oral candidiasis:
2004; dd, P asthma; high-dose ICS; C 320 bid C640 > P (p = 0.0008); P ≡ C320 ≡ C640 < F
Bernstein et al n = 531 FEV1 40%–65% F 440 bid F > P p = (0.0001) HPA function:
2005; predicted; SR: C320, C640, F > P C320 ≡ C640 ≡ F  
Busse et al 2005 ≥ 12 years old (p < 0.0001 AD) ≡ P ≡ BL
Resc: C320, C640, F > P AQLQ: C320, C640,
(p < 0.0001 AD) F > P (p < 0.0001)
LOE: C320, C640, F > P
(p < 0.0001 AD)Therapeutics and Clinical Risk Management 2006:2(1) 32
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Table 1 continued
Study
design Dosages Overall Tolerability and
Study (n) Inclusion criteria (µg) Main results efficacy quality of life
Gelfand et al 2005;  mc, r, pg, Children with mild to C 40 od FEV1: C40 = P (p = 0.26), C > P Well tolerated in all
Miller et al 2005; db, P severe persistent C 80 od C80 > P (p = 0.01), groups
Shapiro et al 2005 n = 1031 asthma/FEV1 60%–85% C 160 od C160 > P (p = 0.008) Oral candidiasis:
predicted; SR: C40 > P (p = 0.0022), 3 cases (all C) in 1025
4–11 years old C80 > P (p < 0.0001), patients
C160 > P (p < 0.0001) Serum and urinary
Resc: C40, C80, C160 < P cortisol levels:
LOE: C40, C80, C160 < PP  ≡ C40, C80, C160
(p = 0.02 AD) Pediatric AQLQ (in
793 children ≥ 7 years
old): C40 > P
(p = 0.01), C80 > P
(p = 0.004), C160 > P
(p = 0.002)
Pedersen, Garcia,  mc, r, db Children and C 80 bid PEFam: C ≡ F > BL (p < 0.0001) C ≡ F > BL Adverse events:
et al 2004; n = 556 adolescents with mild- F 88 bid PEFpm: C ≡ F > BL (p < 0.0001) C ≡ F
Pedersen, to-severe asthma/2–4 FEV1: C ≡ F > BL (p < 0.0001) Urinary cortisol
Gyurkovits, weeks without ICS; SR: C ≡ F > BL (p < 0.0001) levels: Cc > F
et al 2004 FEV1 50%–90% Resc: C ≡ F < BL (p < 0.0001) (p = 0.0062)
predicted /6 to
15 years old
a 8-week study
b C produced more symptom-free days
c C increased levels from BL
Abbreviations: AD, all/both drug doses; am, morning; AQLQ, Juniper Asthma Quality of Life Questionnaire; bid, twice daily; BL, baseline; Bu, budesonide; C,
ciclesonide ex-actuator dose via HFA-MDI unless otherwise stated; db, double-blind; dd, double-dummy; FEV1,forced expiratory flow in one second; F, fluticasone
propionate ex-actuator dose via MDI; FVC, forced vital capacity; HPA, hypothalamic pituitary adrenal; ICS, inhaled corticosteroid; LOE, discontinuation due to lack of
efficacy; mc, multicenter; n, number of patients; NR, not reported; od, once daily; P, placebo; PEF, peak expiratory flow; pg, parallel group; pm, evening; r, randomized;
Resc, need for rescue medications; SR, symptom control (reduction of symptoms).
regimens of ciclesonide 320 µg (ex-actuator HFA MDI) and
budesonide 400 µg (via Turbuhaler) were compared in a
study of 359 patients with asthma who had been pretreated
with high-dose ICS (Boulet et al 2003). Ciclesonide
produced equivalent FEV1 results to budesonide, but better
FVC results (p < 0.01), and more symptom-free days
(p = 0.0288), and there was no difference between the two
drugs in the need for rescue medication.
Ciclesonide 160 µg once daily in the evening has been
compared with fluticasone 88 µg twice daily (ex-actuator
HFA MDI both drugs) in 529 patients with asthma (Buhl et
al 2004). The results showed that ciclesonide produced
significant improvements from baseline in FEV1, FVC, and
morning PEF (all p < 0.0001 compared with baseline) that
were equivalent to fluticasone. Equivalent symptom
reduction and need for rescue medication were also observed
with the two drugs. Similar results were observed in a study
of 697 patients with persistent asthma (Magnussen et al
2005). In this study, equivalency to fluticasone (88 µg twice
daily) was found with ciclesonide 80 and 160 µg once daily
(all drugs ex-actuator MDI). Ciclesonide has also been
compared with fluticasone in 531 patients in severe
persistent asthma (Busse et al 2005). Following 12 weeks’
treatment, and compared with placebo, FEV1 improved with
fluticasone 440 µg (ex-actuator CFC MDI) twice daily
(p < 0.0001) and dose-dependently with twice daily
ciclesonide (ex-actuator HFA MDI) 160 µg (p = 0.0374) or
320 µg (p = 0.0008). All 3 regimens improved asthma
symptoms and need for albuterol compared with placebo
(p < 0.0001 for all comparisons).
Efficacy in children
Ciclesonide (40, 80, or 160 µg ex-actuator HFA MDI once
daily) was compared with placebo in a 12-week study of
1031 children with persistent asthma (Shapiro and Bensch
2005). FEV1 significantly improved compared with placebo
in all doses. There were fewer discontinuations due to lack
of efficacy with ciclesonide, as well as significantly less
asthma symptoms, less need for albuterol, and a decrease
in nocturnal awakenings, compared with placebo. AnotherTherapeutics and Clinical Risk Management 2006:2(1) 33
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12-week study compared ciclesonide 80 µg twice daily with
fluticasone 88 µg twice daily (both drugs ex-actuator HFA
MDI) in 556 children and adolescents with mild to severe
asthma (Pedersen, Garcia, et al 2004). Compared with
baseline both drugs significantly improved FEV1 and
morning and evening PEF. Asthma symptoms and need for
rescue medications were lowered with both drugs. The
authors concluded that the drugs showed equivalent efficacy
in this patient population.
Quality of Life
Quality of life (QoL) assessment in 2 of the studies in Table 1
showed that ciclesonide improved QoL significantly over
placebo and was comparable with fluticasone in patients
aged 12 years or older (Bernstein et al 2005; Nayak et al
2005). Ciclesonide also improved QoL in children aged 7
years or older in a placebo-controlled study in pediatric
patients (Miller et al 2005).
Tolerability
A low propensity for typical ICS adverse events was
presented in the pharmacodynamics section of this review.
In addition, ciclesonide was well tolerated in all of the
clinical trials reported in Table 1. For example, in the
placebo-controlled study of 329 patients with persistent
asthma, adverse events with ciclesonide (160 or 640 µg ex-
actuator HFA MDI once daily for 12 weeks) were mostly
mild or moderate and were unrelated to study medication,
and severe adverse events were reported in 7% or less of all
patients (Chapman et al 2005). The most frequent adverse
events included asthma (14% and 13% in ciclesonide 160
and 640 µg groups, respectively, compared with 29% in
the placebo group), headache (16%, 13%, and 17%,
respectively), upper respiratory tract infection (6%, 8%, and
13%), and rhinitis (15%, 9%, and 13%). Oral candidiasis
did not occur, and cortisol levels were similar in all groups.
Table 1 shows the key tolerability results from published
studies in adults and children. At the dosages used,
ciclesonide did not exert any untoward adverse effects, and
did not suppress cortisol production. A pooled analysis of
studies shows that among 6846 patients with asthma who
were treated with ciclesonide, another ICS, or placebo, the
incidence of oral adverse events was similar for ciclesonide
and placebo-treated patients, and that other ICS produced
the most oral candidiasis and hoarseness (Figure 4)
(Engelstatter et al 2004). Another pooled analysis among
7732 patients with asthma concluded that ciclesonide and
placebo recipients experienced similar incidences of adverse
events (Hafner et al 2004).
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Figure 4 Occurrence of oropharyngeal adverse events with ciclesonide. Derived from a pooled analysis of the number of oral adverse events per patient year
(adjusted for exposure time) in a total of 6846 patients with asthma who received placebo, ciclesonide, or active comparator (budesonide, beclomethasone
dipropionate, or fluticasone propionate) in phase II and III studies (Engelstatter et al 2004). This subanalysis of 2755 patients who received placebo (n = 388),
ciclesonide 80–640 µg/day (n = 1621), or fluticasone propionate 176 or 880 µg/day (n = 746) for 12 weeks showed that the incidence of oral adverse events associated
with ciclesonide 640 µg/day (n = 465) was lower than with fluticasone 880 µg/day (n = 483) (Engelstatter R, Banerji D, Stenijans VW. 2004. Low incidence of
oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis [abstract]. Am J Respir Crit Care Med. 169:A92. Copyright ©
2004. Reproduced with permission from AJRCCM).Therapeutics and Clinical Risk Management 2006:2(1) 34
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The long-term safety profile of once-daily ciclesonide
during a 52-week multicenter, open-label extension study
in 226 patients was similar to that in the 12-week studies.
Overall, 13 patients (5.75%) experienced at least 1 adverse
event that was considered possibly related to ciclesonide
treatment, including one case each of oral candidiasis and
pharyngitis. There were no clinically relevant changes from
baseline to study endpoint in HPA function as measured by
24-hour urinary free cortisol levels (corrected for creatinine)
and peak serum cortisol concentrations following
cosyntropin 1 µg stimulation (Berger et al 2005).
Patient support/disease
management programs
Current asthma treatment guidelines incorporate a stepwise
approach to therapy, based on asthma severity (BTS & SIGN
2004; GIA 2004). Inhaled corticosteroids are recommended
from the second step onwards, where regular controller
Figure 5 Clinical summary of ciclesonide in asthma. All features and comments are derived from referenced information in the text.
Abbreviations: des-CIC, desisobutyryl-ciclesonide; ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity;
HFA, hydrofluoroalkane; PEF, peak expiratory flow.
Key pharmacological features 
Smaller particle size than other non-
HFA inhaled ICS 
  Greater lung deposition (>50%) than 
older ICS 
  Less oral exposure than older ICS 
Prolonged antiinflammatory activity 
  Converted to active form, des-CIC, 
by esterases in the lung 
  Des-CIC forms lipid conjugates in 
the lung that prolong activity 
 Once-daily  dosing 
Low systemic exposure 
Efficacy 
Overall
  Once-daily dosing improves FEV1
FVC, PEF, symptoms, and use of 
rescue medications 
  Once-daily dosing may improve 
patient compliance 
Adults
CICLESONIDE
Tolerability  
  Well tolerated with lower incidence of oropharyngeal adverse 
effects than older ICS 
Quality of life 
  Improves quality of life 
in adults and children Therapeutics and Clinical Risk Management 2006:2(1) 35
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therapy is required. Poor adherence to ICS is common and
is associated with negative outcomes in patients with asthma
(Williams et al 2004). Complex treatment regimens are
considered to be an important factor underlying patient
noncompliance, and once-daily drug regimens have been
suggested as a means of improving compliance with ICS,
and hence the outcomes of treatment, for patients with
asthma (Campbell 1999). The ciclesonide efficacy and safety
results show that it can be recommended for stepwise asthma
therapy when ICS are required. Once-daily administration
(morning or evening) offers greater patient acceptability than
other twice-daily ICS. The low systemic availability and
high protein binding of ciclesonide (Rohatagi et al 2005)
are features that may explain the low incidence of adverse
events. Figure 5 provides a clinical summary of ciclesonide
based on its pharmacological properties and clinical trial
results.
Conclusion
Ciclesonide has good efficacy equivalent at least to that of
the most widely used ICS medications for the treatment of
asthma: budesonide and fluticasone. Ciclesonide has a
favorable pharmacodynamic and pharmacokinetic profile,
with potential for reduced local and systemic adverse effects
compared with other ICS. In clinical trials, it had
oropharyngeal effects that were similar to placebo, and did
not suppress cortisol production. Initial results from long-
term, open studies are promising, and future trials, including
outcomes data, will enable the role of ciclesonide in asthma
management to be further defined.
In clinical practice, the once-daily dosing regimen of
ciclesonide should aid patient compliance, which could
potentially improve outcomes and QoL for adults and
children with asthma. Overall, ciclesonide offers an
efficacious alternative to ICS for persistent asthma, with a
convenient dosing regimen and the potential for reduced
systemic adverse effects.
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